Iga nephropathy

The FDA has extended the PDUFA goal date for Calliditas Therapeutics AB's (NASDAQ: CALT) application seeking accelerated approval for Nefecon. Nefecon is an oral formulation targeting down-regulation of IgA1 to treat primary IgA Nephropathy (IgAN). The new goal date is...

Chinook Therapeutics Inc (NASDAQ: KDNY) has announced interim data from the ongoing Phase 1/2 study of BION-1301 in patients with IgA Nephropathy (IgAN). The findings were presented at the 58th European Renal Association – European Dialysis and Transplant Association (ERA-EDTA...

Shares of Anthera Pharmaceuticals Inc (NASDAQ: ANTH), a nano-cap bio-pharmaceutical company that focuses on developing and commercializing products to treat serious diseases, soared higher by more than 30 percent on Wednesday. Anthera announced on Tuesday positive data from its Phase 2 BRIGHT-...